Gastroenterology · Duodenal Gastrinoma

Long-Term Surveillance and Follow-Up

At a Glance

After treatment for a duodenal gastrinoma, long-term surveillance helps detect recurrence and manage chronic proton pump inhibitor therapy. Follow-up may include gastrin and other blood tests, imaging, MEN1 screening, and individualized checks of vitamin, bone, and kidney health.

Receiving treatment for a duodenal gastrinoma is a major milestone, but it is not the end of your journey. Because these tumors are part of a complex hormonal system, long-term surveillance is essential to catch any signs of recurrence early and to manage the realities of chronic acid suppression ^[1]^[2].

Monitoring After Surgery

If you had a sporadic gastrinoma removed with the goal of a cure, you might expect to be finished with doctors. However, recurrence requires diligent follow-up. While one large cohort study reported a 37% recurrence rate within five years, your personal probability depends heavily on your specific tumor stage, nodal disease, margins, and MEN1 status ^[1].

Your follow-up will typically include:

Fasting Serum Gastrin: Tracking gastrin levels is an important part of monitoring, but a rising level is not specific for recurrence. PPIs, renal impairment, atrophic gastritis, and other factors can raise it. A rise needs medication review and correlation with symptoms, pH, and imaging ^[2]^[3].
Chromogranin A (CgA): This is a protein released by neuroendocrine cells. While it can be a helpful marker, it is often elevated just from taking Proton Pump Inhibitors (PPIs), so your doctor must interpret it carefully ^[4]^[5].
Imaging: You will likely have periodic scans, such as MRI or CT. If a recurrence is suspected, a Ga-68 DOTATATE PET/CT is highly useful for somatostatin-receptor-positive disease, though it does not detect every recurrence ^[6]^[7].

Lifelong Vigilance for MEN1

If you have MEN1, your surveillance is broader and lifelong. Because the genetic “blueprint” for tumors exists in several organs, you are monitoring for more than just the gastrinoma ^[8]^[9].

Multisystem Checks: You will have biochemical screenings for calcium and parathyroid hormone (PTH) to check for overactive parathyroid glands, as well as prolactin tests for pituitary tumors ^[10]^[11].
Pancreatic Monitoring: MRI is often preferred over CT for long-term monitoring of the pancreas and duodenum to avoid repeated ionizing-radiation exposure ^[12]^[13].

Managing Long-Term PPI Use

Whether your tumor was removed or is being managed with medication, many ZES patients remain on high-dose PPIs for years. While these drugs are life-saving, long-term use requires individualized monitoring based on your dose, duration, diet, symptoms, and other health factors ^[14]^[15]:

Vitamin B12 and Magnesium: Depending on your specific situation, your doctor may check your B12 and magnesium levels ^[16]^[17]. Do not assume you automatically need supplements without testing.
Bone Health: Some studies suggest associations between PPIs and bone outcomes. Discuss with your doctor if a bone density (DEXA) scan is appropriate given your personal fracture risk ^[18]^[19].
Kidney Function: Periodic blood tests may monitor your creatinine and GFR ^[20]^[21].
Crucial Rule: Never stop a life-saving PPI because of an isolated laboratory concern without your specialist’s direct guidance.

Navigating “Scanxiety”

It is completely normal to feel intense anxiety in the days or weeks leading up to your follow-up appointments—a phenomenon often called scanxiety.

The Emotional Toll: Living with a diagnosis that requires chronic monitoring means waiting for the next lab result can feel like waiting for a verdict.
Proactive Coping: Many patients find it helpful to schedule their scans for early in the week and request a specific date for when results will be discussed, reducing the time spent in uncertainty.
Focus on Trends: A single slightly elevated gastrin level isn’t always a crisis; your care team will look at the “trend” over several months and correlate it with your clinical picture.

Surveillance is your safety net. By staying consistent with your follow-ups, you and your medical team can ensure that any changes are caught early and managed effectively ^[11].

Common questions in this guide

What follow-up tests are needed after duodenal gastrinoma surgery?

Your schedule should be individualized based on the tumor stage, whether nearby lymph nodes were involved, whether the surgical edges were clear, and whether you have MEN1, an inherited tumor syndrome. Monitoring may include fasting gastrin and chromogranin A blood tests, periodic MRI or CT, and additional imaging if recurrence is suspected. Your specialist should set the timing and explain each result.

Does a higher gastrin level mean my duodenal gastrinoma has come back?

Not necessarily. Proton pump inhibitors, reduced kidney function, atrophic gastritis, and other factors can raise gastrin without proving that the tumor has returned. Your team will interpret the result with your medicines, symptoms, stomach-acid measurements, and imaging.

Can my PPI change the blood tests used for gastrinoma surveillance?

Yes. Proton pump inhibitors can raise gastrin and chromogranin A, a protein released by neuroendocrine cells, so these results need careful interpretation. Do not stop a prescribed PPI because of a lab result unless your specialist tells you to do so.

What monitoring is needed if I have MEN1 as well as a duodenal gastrinoma?

If you have MEN1, surveillance is lifelong and covers several organs, not only the gastrinoma. Blood tests may include calcium, parathyroid hormone, and prolactin, while MRI is often used to monitor the pancreas and duodenum over time. Your care team should coordinate these checks with your tumor follow-up.

Which health checks matter during long-term PPI treatment?

Depending on your dose, treatment duration, diet, symptoms, and other health factors, your clinician may check vitamin B12, magnesium, creatinine, and estimated GFR, a measure of kidney function. A bone-density scan may be appropriate if your personal fracture risk supports it, and supplements should not be started automatically without testing.

What symptoms should I report between gastrinoma follow-up visits?

Report breakthrough symptoms such as diarrhea or stomach pain to your doctor. Your team can interpret these symptoms alongside gastrin results and imaging.

How can I cope with anxiety while waiting for follow-up scan results?

Scanxiety is common during long-term monitoring. Scheduling scans early in the week and agreeing on a date to discuss the results can reduce the time spent waiting, while looking at gastrin trends over time can be more useful than reacting to one slightly elevated result. Ask your care team who will review your labs and how results will be communicated.

Get notified when new evidence is published on duodenal gastrin-producing neuroendocrine tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Recurrence can occur after duodenal gastrinoma surgery, so follow-up timing should reflect tumor stage, nodal disease, surgical margins, and MEN1 status.
Fasting gastrin and chromogranin A results can be affected by proton pump inhibitors and other conditions, so a rise needs clinical context rather than automatic assumptions about recurrence.
Periodic MRI or CT may be used, while Ga-68 DOTATATE PET/CT can help find somatostatin-receptor-positive disease when recurrence is suspected.
MEN1 requires lifelong multisystem surveillance, including calcium and parathyroid hormone tests, prolactin testing, and imaging of the pancreas and duodenum.
Long-term PPI monitoring may include vitamin B12, magnesium, kidney function, and bone health, and prescribed PPIs should not be stopped without specialist guidance.

References (21)

1
Recurrence after surgical resection of nonmetastatic sporadic gastrinoma: Which prognostic factors and surgical procedure?
Robin L, Sauvanet A, Walter T, et al.
Surgery 2023; (173(5)):1144-1152 doi:10.1016/j.surg.2022.12.030.
PMID: 36781315
2
All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update.
Chatzipanagiotou O, Schizas D, Vailas M, et al.
Journal of neuroendocrinology 2023; (35(4)):e13267 doi:10.1111/jne.13267.
PMID: 37042078
3
Secretin Stimulation Test and Early Diagnosis of Gastrinoma in MEN1 Syndrome: Survey on the MEN1 Florentine Database.
Giusti F, Cioppi F, Fossi C, et al.
The Journal of clinical endocrinology and metabolism 2022; (107(5)):e2110-e2123 doi:10.1210/clinem/dgab903.
PMID: 34922358
4
Gastrointestinal neuroendocrine tumors in 2020.
Ahmed M
World journal of gastrointestinal oncology 2020; (12(8)):791-807 doi:10.4251/wjgo.v12.i8.791.
PMID: 32879660
5
Hypertrophic Gastric folds with Hypomagnesemia, linking the dots.
Zafar M, Muhammad T, Saher NU, Toqeer M
Pakistan journal of medical sciences 2021; (37(4)):1237-1240 doi:10.12669/pjms.37.4.3984.
PMID: 34290814
6
Imaging surveillance in multiple endocrine neoplasia type 1: Ten years of experience with somatostatin receptor positron emission tomography.
Said M, Krogh J, Feldt-Rasmussen U, et al.
Journal of neuroendocrinology 2023; (35(8)):e13322 doi:10.1111/jne.13322.
PMID: 37564005
7
Nuclear Imaging of Neuroendocrine Tumors.
Pollard J, McNeely P, Menda Y
Surgical oncology clinics of North America 2020; (29(2)):209-221 doi:10.1016/j.soc.2019.11.007.
PMID: 32151356
8
Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old.
Falchetti A
F1000Research 2017; (6()) doi:10.12688/f1000research.7230.1.
PMID: 28184288
9
American Association of Clinical Endocrinology Consensus Statement on Management of Multiple Endocrine Neoplasia Type 1.
Del Rivero J, Gangi A, Annes JP, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; doi:10.1016/j.eprac.2025.02.001.
PMID: 40232217
10
The Importance of Periodical Screening for Primary Hyperparathyroidism in a Pituitary Tumor Cohort in Searching Patients With MEN1 and Its Genetic Profile.
Damianse SSP, Nascimento GC, Rocha VCC, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(5)):509-514 doi:10.1016/j.eprac.2022.02.010.
PMID: 35247589
11
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice.
Brandi ML, Pieterman CRC, English KA, et al.
The lancet. Diabetes & endocrinology 2025; (13(8)):699-721 doi:10.1016/S2213-8587(25)00119-6.
PMID: 40523372
12
Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice.
van Beek DJ, Pieterman CRC, Wessels FJ, et al.
Frontiers in endocrinology 2022; (13()):926491 doi:10.3389/fendo.2022.926491.
PMID: 36277719
13
Diagnosing Nonfunctional Pancreatic NETs in MEN1: The Evidence Base.
van Treijen MJC, van Beek DJ, van Leeuwaarde RS, et al.
Journal of the Endocrine Society 2018; (2(9)):1067-1088 doi:10.1210/js.2018-00087.
PMID: 30202829
14
Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES.
Ito T, Ramos-Alvarez I, Jensen RT
Cancers 2023; (15(5)) doi:10.3390/cancers15051377.
PMID: 36900170
15
Total gastrectomy for severe proton pump inhibitor-induced hypomagnesemia in a MEN1/Zollinger Ellison syndrome patient.
Perrier M, Delemer B, Deguelte S, et al.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021; (21(1)):236-239 doi:10.1016/j.pan.2020.12.002.
PMID: 33309626
16
Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin B12 Deficiency in Zollinger-Ellison Syndrome (ZES) Patients.
Ito T, Ramos-Alvarez I, Jensen RT
International journal of molecular sciences 2024; (25(13)) doi:10.3390/ijms25137286.
PMID: 39000391
17
Severe Hypomagnesemia Caused by Proton-Pump Inhibitors in a Patient With an Ostomy.
Ali K, Ali AA, Jaikaransingh V
Cureus 2024; (16(3)):e55856 doi:10.7759/cureus.55856.
PMID: 38590468
18
Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN, Islam MM, Yang HC, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2019; (30(1)):103-114 doi:10.1007/s00198-018-4788-y.
PMID: 30539272
19
Establishing the Association Between Osteoporosis and Peptic Ulcer Disease: A Systematic Review.
Teresa Selvin S, Thomas S, Bikeyeva V, et al.
Cureus 2022; (14(7)):e27188 doi:10.7759/cureus.27188.
PMID: 36039217
20
Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.
Maideen NMP
Chonnam medical journal 2023; (59(2)):115-127 doi:10.4068/cmj.2023.59.2.115.
PMID: 37303818
21
Proton Pump Inhibitors: Review of Emerging Concerns.
Nehra AK, Alexander JA, Loftus CG, Nehra V
Mayo Clinic proceedings 2018; (93(2)):240-246 doi:10.1016/j.mayocp.2017.10.022.
PMID: 29406201

This page is for informational purposes only and does not constitute medical advice. It explains long-term follow-up after duodenal gastrinoma; your specialists should determine your surveillance schedule and interpret your blood tests, scans, MEN1 screening, and PPI monitoring.

Guide Contents